MedTrace Logo

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

NCT06560489 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-11

No results posted yet for this study

Summary

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Conditions

Interventions

DRUG

Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Sponsors & Collaborators

  • Institute of Pathogen Biology, Beijing, China

    collaborator OTHER

  • Shanxi Kangbao Biological Product Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qingxia Zhao, Doctor · Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2025-01-10
Completion
2025-08-22

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06560489 on ClinicalTrials.gov